Volume 24, Number 7—July 2018
Research
Pneumococcal Meningitis in Adults after Introduction of PCV7 and PCV13, Israel, July 2009–June 20151
Figure 5
![Serotypes associated with meningitis and nonmeningitis invasive pneumococcal disease, Israel, July 1, 2009–June 30, 2015. Only major serotypes (those totaling >3% of all Streptococcus pneumoniae isolates from all study years) were included. *p<0.1. †p<0.05. ‡p<0.005. §Serotypes covered by pneumococcal conjugate vaccine 13.](/eid/images/17-0721-F5.jpg)
Figure 5. Serotypes associated with meningitis and nonmeningitis invasive pneumococcal disease, Israel, July 1, 2009–June 30, 2015. Only major serotypes (those totaling >3% of all Streptococcus pneumoniae isolates from all study years) were included. *p<0.1; †p<0.05; ‡p<0.005; §serotypes covered by pneumococcal conjugate vaccine 13.
1Some results from this study were presented at the 10th International Symposium on Pneumococci and Pneumococcal Diseases, June 26–30, 2016, Glasgow, Scotland.
2Additional members of the Israeli Adult Invasive Pneumococcal Disease Group are listed at the end of this article.
Page created: June 18, 2018
Page updated: June 18, 2018
Page reviewed: June 18, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.